Bio Plus Co., Ltd (KOSDAQ:099430)
3,220.00
0.00 (0.00%)
Sep 11, 2026, 3:30 PM KST
Bio Plus Revenue
Bio Plus had revenue of 25.40B KRW in the quarter ending June 30, 2026, with 22.87% growth. This brings the company's revenue in the last twelve months to 99.15B, up 11.20% year-over-year. In the year 2025, Bio Plus had annual revenue of 90.90B with 36.87% growth.
Revenue (ttm)
99.15B
Revenue Growth
+11.20%
P/S Ratio
2.00
Revenue / Employee
615.85M
Employees
161
Market Cap
198.16B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.90B | 24.49B | 36.87% |
| Dec 31, 2024 | 66.41B | 1.37B | 2.10% |
| Dec 31, 2023 | 65.04B | 8.32B | 14.68% |
| Dec 31, 2022 | 56.72B | 19.30B | 51.58% |
| Dec 31, 2021 | 37.42B | 13.05B | 53.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Value Added Technology | 441.04B |
| Vieworks | 244.28B |
| Boditech Med | 174.78B |
| WON TECH | 167.35B |
| Dongbang Medical | 125.12B |
| Shinhung | 105.89B |
| Curexo | 77.74B |
| JETEMA, | 76.58B |